Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Taxes (2016 - 2020)

Harvard Bioscience (HBIO) has disclosed Change in Taxes for 11 consecutive years, with -$241000.0 as the latest value for Q3 2020.

  • On a quarterly basis, Change in Taxes fell 4.78% to -$241000.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $330000.0, a 273.68% increase, with the full-year FY2019 number at -$363000.0, down 159.31% from a year prior.
  • Change in Taxes was -$241000.0 for Q3 2020 at Harvard Bioscience, down from $337000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $555000.0 in Q3 2018 to a low of -$741000.0 in Q2 2019.
  • A 5-year average of $19368.4 and a median of $6000.0 in 2020 define the central range for Change in Taxes.
  • Peak YoY movement for Change in Taxes: skyrocketed 578.38% in 2017, then crashed 1057.41% in 2018.
  • Harvard Bioscience's Change in Taxes stood at -$37000.0 in 2016, then surged by 578.38% to $177000.0 in 2017, then soared by 126.55% to $401000.0 in 2018, then tumbled by 43.14% to $228000.0 in 2019, then plummeted by 205.7% to -$241000.0 in 2020.
  • Per Business Quant, the three most recent readings for HBIO's Change in Taxes are -$241000.0 (Q3 2020), $337000.0 (Q2 2020), and $6000.0 (Q1 2020).